Pioneering Nuclear Medicine: Dr.Giraudet and Colleagues Advance Targeted Therapies for Cancer
Table of Contents
The landscape of cancer treatment is undergoing a significant shift, driven by advancements in targeted radionuclide therapies and diagnostic imaging. Research led by Dr. Alain Luc Giraudet and a collaborative network of specialists is at the forefront of these innovations, impacting treatment strategies for prostate, thyroid, neuroblastoma, renal, and other solid tumors.
Revolutionizing Prostate Cancer Treatment with PSMA Targeting
Prostate-specific membrane antigen (PSMA) has emerged as a crucial target in the fight against prostate cancer,notably in cases of metastatic castration-resistant disease.A 2021 study, co-authored by Dr. Giraudet, demonstrated the efficacy of 177Lu-PSMA therapy in improving outcomes for patients with PSMA-positive metastatic castration-resistant prostate cancer. Further refining diagnostic capabilities, over 18F-fluorocholine PET/CT is increasingly utilized for localizing prostate cancer recurrence.This represents a significant step forward in accurately identifying tumor sites for targeted therapy. The PACAP Study, released in April 2024, investigated the activity of Lutetium-177 PSMA in patients previously treated with cabazitaxel, revealing key determinants of treatment outcomes. Researchers are also refining dosimetry techniques, as evidenced by work published in May 2022, focusing on patient-specific assessments adapted to variable SPECT/CT time-points for 177Lu-DOTATATE therapy.
Expanding the Reach of Targeted Therapy Beyond Prostate Cancer
The promise of targeted radionuclide therapy extends beyond prostate cancer. Dr. Giraudet’s team is actively investigating its request in other malignancies. A 2023 study published in EMBO Molecular Medicine detailed a novel approach utilizing netrin-1-targeted SPECT/CT for internal radiotherapy in advanced solid tumors. This research opens avenues for treating cancers that have historically been difficult to target.
In February 2024, a phase I/II study (PRadR) evaluated PSMA-targeted radionuclide therapy in patients with metastatic clear cell renal cancer, demonstrating promising initial results. Furthermore, research published in April 2025 revealed the expression of PSMA in both primary and metastatic renal cell cancer, suggesting a broader potential for PSMA-targeted therapies in this disease.
Advancements in Neuroblastoma and Thyroid Cancer Management
Dr. Giraudet’s contributions also extend to pediatric oncology and endocrine disorders.A Phase II study, published in November 2023, examined the efficacy of 131 I-metaiodobenzylguanidine (MIBG) combined with topotecan for relapsed or refractory neuroblastoma, a challenging childhood cancer.
Significant progress has also been made in the management of low-risk thyroid cancer.A landmark study published in The New England Journal of Medicine in March 2022, and followed up with 5-year data in January 2025, demonstrated that thyroidectomy without radioiodine is a safe and effective treatment option for patients with low-risk thyroid cancer. This finding has the potential to reduce the need for lifelong thyroid hormone replacement therapy and minimize potential side effects.
Optimizing Imaging and Dosimetry for Enhanced Treatment Precision
Accurate imaging and precise dosimetry are critical for maximizing the effectiveness of targeted radionuclide therapies. Researchers, including Dr. Giraudet, are continually refining these techniques. A September 2023 study focused on the performance of a 360° CZT camera for monitoring Lu-PSMA treatment, demonstrating its potential to improve treatment monitoring. Similarly, work published in May 2022 detailed methods for adapting patient-specific dosimetry to variable SPECT/CT time-points for 177Lu-DOTATATE therapy.
The ongoing research led by Dr. Giraudet and collaborators represents a paradigm shift in cancer treatment, moving towards more personalized and effective therapies with reduced side effects. These advancements offer renewed hope for patients battling a wide range of cancers, and underscore the vital role of nuclear medicine in the future of oncology.
